<sup>131</sup>Ⅰ治疗非Graves'甲状腺功能亢进及非毒性甲状腺肿后诱发Graves'病

覃伟武

¹³¹Ⅰ治疗非Graves'甲状腺功能亢进及非毒性甲状腺肿后诱发Graves'病

覃伟武

文章导航 > 国际放射医学核医学杂志 > 2006, 30 > 6: (325-327)

引用本文:

Citation:

¹³¹Ⅰ治疗非Graves'甲状腺功能亢进及非毒性甲状腺肿后诱发Graves'病

覃伟武

530021 南宁, 广西医科大学第一附属医院核医学科
中图分类号: R817.8

Induction of Graves' disease in patients with non-autoimmune hyperthyroidism or nontoxic goiter after radioiodine treatment

QIN Wei-wu

Department of Nuclear Medicine, The Fist Affiliated Hospital of Guanxi Medical University, Nanning 530021, China
CLC number: R817.8

摘要: ¹³¹Ⅰ治疗非Graves'甲亢及非毒性甲状腺肿后数月,少部分患者体内出现促甲状腺激素受体抗体并诱发Graves'病(GD),发病率在0.05%-5%之间。其发病机制假说有通过自身免疫反应介导等。通过监测体内甲状腺自身抗体水平变化、甲状腺显像,可以预测¹³¹Ⅰ治疗后GD的发生。其治疗方法有抗甲状腺药物治疗、再次放射性¹³¹Ⅰ治疗、手术治疗。
- 碘放射性同位素 /
- 放射疗法 /
- 格雷夫斯病 /
- 甲状腺功能亢进症 /
- 甲状腺肿
Abstract: Thyrotropin receptors antibodies may occur and induce Graves' disease (GD) several months after radioiodine therapy in a small number of patients with nontoxic goiter. The prevalence of radiation-induced GD is between 0.05% and 5%. The hypothesis of this disease includes induction by autoimmune reaction and others. Detection of the thyroid autoantibodise or of ^99mTc pertechnetate scan can forecast the appearance of GD. Anfithyroid drugs,again radioiodine therapy and surgery are the treatments.
- Iodine radioisotopes /
- Radiotherapy /
- Graves' disease /
- Hyperthyroidism /
- Goiter
本作品遵循Signature-Non-Commercial Use 4.0 International (CC BY-NC 4.0)协议

[1]	Hegodus L, Bonnema SJ, Bennedbsek FN, et al. Management of simple nodular goiter:current status and future perspectives.Endocr Rev, 2003, 24(1):102-132.
[2]	Meller J, Siefker U, Hamsnn A, et al. Incidence of radioiodine induced Graves' disease in patients with multinodular toxic goiter.Exp Clin Endocrinol Diabetes, 2006, 114(5):235-239.
[3]	Wallaschofsld H, Muller D, Georgi P, et al. Induction of TSH-receptor antibodies in patients with toxic multinodular goitre by radioiodine treatment. Horm Metab Res, 2002, 34(1):36-39.
[4]	Cseke B, Balazs C. Development of Basedows disease after radioiodine therapy for nodular goiter. Orv Hetil, 2003, 144(47):2327-2329.
[5]	Schmidt M, Gorbauch E, Dietlein M, et al. Incidence of postradioiodine immunogenic hyperthyroidism/Graves' disease in relation to a temporary increase in thyrotropin receptor antibodies after radioiodine therapy for autonomous thyroid disease. Thyroid, 2006, 16(3):281-288.
[6]	Dunkelmann S, Wolf R, Koch A, et al. Incidence of radiationinduced Graves' disease in patients treated with radioiodine for thyroid autonomy before and after introduction of a high-sensitivity TSH receptor antibody assay. Eur J Nucl Med Mol Imaging, 2004,31(10):1428-1434.
[7]	Nygoard B, Knudsen JH, Hegedus L, et al. Thyrotropin receptor antibodies and Graves' disease, a side-effect of ¹³¹Ⅰ treatment in patients with nontoxic goiter. J Clin Endocrinol Metab, 1997, 82(9):2926-2930.
[8]	Nygaard B, Faber J, Veie A, et al. Transition of nodular toxic goiter to autoimmune hyperthyroidism triggered by ¹³¹Ⅰ therapy.Thyroid, 1999, 9(5):477-481.
[9]	Weiss M, Gorges R, Hirsch C, et al. Incidence of immunogenic hyperthyroidism after radioiodine therapy of focal thyroid gland autonomy. Results of a multicenter study. Med Klin (Munich), 1999,94(5):239-244.
[10]	Giovanella L, Ceriani L, C, arancini S. Evaluation of the 2nd generation radio-receptional assay for anti-TSH receptor antibodies(TRAb) in autoimmune thyroid diseases. Q J Nucl Med, 2001, 45(1):115-119.
[11]	Rapoport B, McLachlan S M. Thyroid autoimmunity. J Clin Invest, 2001, 108(9):1253-1259.
[12]	Custro N, Ganci A, Scafidi V, et al. Relapses of hyperthyroidism in patients treated with radioiodine for nodular toxic goiter:relat-ion to thyroid autoimmunjty. J Endocrinol Invest, 2003, 26(2):106-110.
[13]	Pedersen IB, Knudsen N, Jorgensen T, et al. Thyroid peroxidase and thyroglobin autoanfibodies in a large survey of populations with mild and moderate iodine deficiency. Clin Endocrinol (Oxt),2003, 58(1):36-42.
[14]	Hollower JG, Staehling NW, Flanders WD, et al. Serum thyrotropin, thyrox-ine and thyroid antibodies in the United States population (1988-1994):NHANES IL J Clin Endocrinol Metab,2002, 87(2):489-499.
[15]	Hirsch C, Spyra JL, Langhammer HR, et al. Occurrence of immune hyperthyroidism after radioiodine therapy of autonomous goiter.Med Klin (Munich), 1997, 92(3):130-137.

[1]	孙琦婷 , 赵德善 . Graves病甲状腺功能亢进症与血糖代谢. 国际放射医学核医学杂志, 2010, 34(3): 143-147. doi: 10.3760/cma.j.issn.1673-4114.2010.03.004
[2]	赵炎 , 王俊起 , 沈婕 . Graves病的¹³¹I治疗和抗甲状腺药物治疗:随机对照试验荟萃分析. 国际放射医学核医学杂志, 2017, 41(6): 389-395, 429. doi: 10.3760/cma.j.issn.1673-4114.2017.06.003
[3]	管樑 , 陈刚 . 4项甲状腺自身抗体的变化特征及联合半定量评分在格雷夫斯甲亢¹³¹I治疗后疗效的相关性评估中的临床应用价值. 国际放射医学核医学杂志, 2023, 47(12): 746-751. doi: 10.3760/cma.j.cn121381-202209019-00376
[4]	张晗玉 , 段炼 . ¹³¹I治疗格雷夫斯病剂量确定方法的探讨. 国际放射医学核医学杂志, 2021, 45(11): 721-727. doi: 10.3760/cma.j.cn121381-202011023-00121
[5]	王越 , 晋建华 , 李思进 , 刘建中 , 武志芳 , 陆克义 , 李江萍 . 甲状腺24h摄碘率与¹³¹I治疗Graves甲亢疗效相关性研究. 国际放射医学核医学杂志, 2015, 39(6): 442-446. doi: 10.3760/cma.j.issn.1673-4114.2015.06.002
[6]	田琦 , 蒋宁一 , 郑丽 . 265例精细个体化¹³¹I治疗Graves甲亢的疗效观察. 国际放射医学核医学杂志, 2016, 40(4): 259-262. doi: 10.3760/cma.j.issn.1673-4114.2016.04.004
[7]	陈美言 , 李雪娜 , 李亚明 . Graves甲亢¹³¹I治疗后甲状腺功能的变化特点及其与治疗前抗体水平的关系. 国际放射医学核医学杂志, 2021, 45(1): 18-23. doi: 10.3760/cma.j.cn121381-202003035-000015
[8]	王秉攀 , 陆克义 . 自主功能性甲状腺结节的诊断与¹³¹I治疗进展. 国际放射医学核医学杂志, 2023, 47(8): 509-514. doi: 10.3760/cma.j.cn121381-202211011-00327
[9]	陈丹云 , 静进 . 甲状腺功能亢进症治疗方法的选择. 国际放射医学核医学杂志, 2007, 31(4): 228-231.
[10]	孟召伟 , 谭建 . 解读美国甲状腺协会和临床内分泌医师协会2011年甲亢诊治指南. 国际放射医学核医学杂志, 2011, 35(4): 193-201. doi: 10.3760/cma.j.issn.1673-4114.2011.04.001
[11]	潘香颖 , 李慧贞 . 甲状腺功能亢进症伴肝功能受损的¹³¹I治疗疗效. 国际放射医学核医学杂志, 2009, 33(3): 179-180. doi: 10.3760/cma.j.issn.1673-4114.2009.03.013

点击查看大图

计量

文章访问数: 1422
HTML全文浏览量: 79
PDF下载量: 3

¹³¹Ⅰ治疗非Graves'甲状腺功能亢进及非毒性甲状腺肿后诱发Graves'病

覃伟武

530021 南宁, 广西医科大学第一附属医院核医学科

收稿日期: 2006-05-10

关键词:

摘要: ¹³¹Ⅰ治疗非Graves'甲亢及非毒性甲状腺肿后数月,少部分患者体内出现促甲状腺激素受体抗体并诱发Graves'病(GD),发病率在0.05%-5%之间。其发病机制假说有通过自身免疫反应介导等。通过监测体内甲状腺自身抗体水平变化、甲状腺显像,可以预测¹³¹Ⅰ治疗后GD的发生。其治疗方法有抗甲状腺药物治疗、再次放射性¹³¹Ⅰ治疗、手术治疗。